Eli Lilly and Company (NYSE:LLY) Shares Bought by Prosperitas Financial LLC

Prosperitas Financial LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 5.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 3,249 shares of the company’s stock after purchasing an additional 160 shares during the quarter. Prosperitas Financial LLC’s holdings in Eli Lilly and Company were worth $2,508,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of LLY. AMF Tjanstepension AB increased its position in shares of Eli Lilly and Company by 113.7% during the 3rd quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock valued at $293,964,000 after purchasing an additional 176,552 shares during the period. Values Added Financial LLC increased its position in shares of Eli Lilly and Company by 4.9% during the 3rd quarter. Values Added Financial LLC now owns 366 shares of the company’s stock valued at $324,000 after purchasing an additional 17 shares during the period. Pursue Wealth Partners LLC acquired a new position in shares of Eli Lilly and Company in the 3rd quarter worth $364,000. Lodestar Private Asset Management LLC grew its holdings in shares of Eli Lilly and Company by 17.6% in the 3rd quarter. Lodestar Private Asset Management LLC now owns 1,003 shares of the company’s stock worth $888,000 after acquiring an additional 150 shares during the last quarter. Finally, Highview Capital Management LLC DE grew its holdings in shares of Eli Lilly and Company by 2.7% in the 3rd quarter. Highview Capital Management LLC DE now owns 6,763 shares of the company’s stock worth $5,992,000 after acquiring an additional 181 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $904.76 on Friday. The business’s 50-day moving average price is $811.83 and its two-hundred day moving average price is $848.85. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The company has a market capitalization of $857.87 billion, a P/E ratio of 77.26, a price-to-earnings-growth ratio of 1.40 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has approved a share repurchase plan on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.66%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s payout ratio is 51.24%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on LLY shares. Deutsche Bank Aktiengesellschaft decreased their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Citigroup decreased their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Bank of America restated a “buy” rating and issued a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a report on Friday, January 17th. Finally, Truist Financial lifted their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,000.28.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.